Days to partner up
Roche is looking for new partners in the innovative Norwegian life science scene. Roche is one of the largest pharmaceutical companies in the world with about 800 ongoing clinical trials. Within cancer research and development, this translates into about 500 clinical trials for many different types of cancer. Roche is a member in Oslo Cancer Cluster. […]
The e-health meeting place
Starting next year, Oslo Cancer Cluster will co-power the conference E-health in Norway (EHiN). – This is a natural continuation of the work we do in digitalisation, for a better understanding of cancer and better patient treatment, said Ketil Widerberg, General Manager of Oslo Cancer Cluster, at this year’s conference. The Norwegian Ministry of Health and Care […]
Let us cooperate on precise health technologies
International cooperation is key to fulfilling our vision of making cancer treatments more precise, and giving the patients new treatments more quickly. This opinion piece is written by Ketil Widerberg, General Manager at Oslo Cancer Cluster. It was first published in the Norwegian newspaper Today’s Medicine, Dagens Medisin, 30 October 2018. The countries in Northern Europe have […]
– An idea needs to attract investors
Meet Thomas Andersson, our new Senior Advisor Business Development. How could he be of help to your startup company? — The most important thing I do is to get the startup companies rolling. Thomas Andersson, the new Senior Advisor for Business Development at Oslo Cancer Cluster and Oslo Cancer Cluster Incubator, looks dead serious as […]
T-cells and the Nobel Price
What does the Nobel Prize have to do with cancer research in Oslo Cancer Cluster? This year the Nobel Prize for Physiology and Medicine was awarded to James P. Allison and Tasuku Honjo for their work on unleashing the body’s immune system to attack cancer. This was a breakthrough that has led to an entirely new class […]
Prestigious partnership for Vaccibody
Oslo Cancer Cluster member Vaccibody is entering into a clinical collaboration with the American biopharmaceutical company Nektar Therapeutics. The aim of the collaboration is to explore positive effects from the combination of Vaccibody’s personalized cancer vaccine VB10.NEO and Nektar Therapeutics cancer drug NKTR-214. Pre-clinical results of the combination are very positive and the collaboration will […]
